Methods: Twenty-two individuals with APS with or without other associated autoimmune disease (20 females, two males, median age 55 (range 18-70) years) had blood samples taken before and 12 weeks after starting HCQ 200mg. Plasma was stored at -80 o C and thawed to measure TF using Imubind TF kit (Invitech Ltd, Cambridgeshire, UK). The assay was performed according to the manufacturer's instructions. Patient characteristics are outlined in table 1. Statistical analysis was performed using SPSS Version 22. For continuous normally distributed data a two-tailed student's paired t-test was performed. A value of p=0.05 was considered as significant. There are no previous data in this area, so we were unable to do a power calculation to work out study size. Our study is therefore a pilot study. Results: Soluble TF levels were above our normal range (40-300 pg/ml) prior to the commencement of HCQ and were significantly reduced (pre level mean (SD) 401.8 (152.8) pg/ml versus post 300.9 (108) pg/ml (p=0.010).
AB0148 INDUCTION OF HO-1 EXPRESSION IN MONOCYTES MIGHT PREVENT KIDNEY DAMAGE IN LUPUS NEPHRITIS (LN)
Objectives: To explore the role of HO-1 in modulating innate immunity through a cytoprotective effect in monocytes of LN nephritis patients. Accordingly, we examined the expression of HO-1 in circulating monocytes, and the effect of HO-1 induction in reactive oxygen species (ROS) production and the phagocytic activity of monocytes from peripheral blood of LN patients and healthy controls (HC). Methods: SLE patients with proliferative LN confirmed by renal biopsy (Class III, IV or V ISN/RPS) were recruited at Hospital Clinico of PUC. All individuals signed an informed consent form. Monocytes were purified from peripheral blood mononuclear cells (PBMCs) of LN patients and HC using pan-monocytes MACS kit. Subpopulations of monocytes and HO-1 expression were measured by FACS. ROS was determined using CellRox Kit. The phagocytic ability of monocytes was assessed by FACS and the total phagocytosis was calculated as the percentage of cells with engulfed beads. Results: We found that monocytes from LN patients show significant differences when compared to HC in all the parameters analyzed. The percentage of CD16+ inflammatory monocytes was higher in LN patients (6.72±0.98%) compared to HC (4.07±0.48%) (p<0.05). HO-1 protein expression is decreased in circulating LN monocytes (4789±911 vs 1572±481, p=0.005). Baseline levels of ROS are elevated in LN monocytes with similar values that the ones found in monocytes from HC treated with a ROS inducer (HC: 3509±584; HC+TBHP: 8436±1909; LN: 8355±1714). Furthermore, phagocytic activity is increased in LN monocytes (77.97±3.31%) compared to HC (39.63±2.75%). Moreover, our preliminary data indicate that HO-1 induction, using cobalt protoporphyrin (CoPP), leads to downregulation of ROS production in LN (∼60%) and HC (∼40%) leaving both in similar levels of ROS production. In addition, phagocytic activity is also decreased in LN and HC monocytes in the presence of CoPP (∼30%). Conclusions: Decreased HO-1 expression in circulating monocytes of LN patients leads to higher ROS production and phagocitic activity. ROS level and phagocytosis are reduced when we induce HO-1 expression with CoPP. We propose that HO-1 induction might exert a cytoprotective role in LN by regulating innate immunity. FONDECYT N°1150173.
